One in the eye for Lucentis? Pfenex says Pfizer takeover will benefit Hospira pact
Pfenex expects its new Lucentis biosimilar partnership to benefit from Pfizer’s economic clout after the Hospira takeover completes.
Pfenex expects its new Lucentis biosimilar partnership to benefit from Pfizer’s economic clout after the Hospira takeover completes.
Exclusive Interview
Big biotech firms risk the empty pipeline pitfalls of old pharma if they protect their drugs from biosimilars rather than invest in innovation, ex-Teva CEO Jeremy Levin warns.